Overall Score

Threat Of New Entrants

High R&D intensity and clinical/regulatory hurdles continue to raise barriers to entry in oncology drug development.

KURA's cash position and current ratio remain strong, supporting ongoing development through a long pipeline cycle.

Bargaining Power Of Suppliers

Specialized clinical trial, manufacturing, and research inputs limit supplier substitutability in this business model.

No material change in supplier dependence is indicated by the latest metrics.

Bargaining Power Of Buyers

Payers and providers retain meaningful pricing leverage because KURA has no commercial-scale product revenue yet.

The company remains dependent on future clinical success rather than current customer concentration, keeping buyer power moderate.

Threat Of Substitutes

Alternative oncology therapies and competing mechanisms of action remain a persistent substitute risk.

The absence of approved, revenue-generating products keeps substitution pressure elevated until clinical differentiation is proven.

Industry Rivalry

Competition among oncology biotech peers remains intense, with many firms pursuing similar targets and indications.

KURA's high R&D spend relative to revenue and continued losses suggest rivalry remains a major constraint on economics.